GAVI’S VACCINE INVESTMENT STRATEGY€¦ · GAVI’S VACCINE INVESTMENT STRATEGY Judith...
Transcript of GAVI’S VACCINE INVESTMENT STRATEGY€¦ · GAVI’S VACCINE INVESTMENT STRATEGY Judith...
www.gavi.org
GAVI’S VACCINE INVESTMENT STRATEGY
Judith Kallenberg, Head of Policy PDVAC 22 June 2017, Geneva
Reach every child
Gavi finances vaccines and immunisation through three routes ($9 Billion in 2016-2020)
2
Health Systems
and Immunisation
Strengthening
Vaccines Technical
assistance
VIS
Innovation
Gavi, the Vaccine Alliance, mission:
3
“To save children’s lives and protect people’s health
by increasing equitable use of vaccines in lower
income countries”
Gavi supports 73 countries, reaching ~80 million children per year
Since 2000: 600,000,000 children immunized 8,000,000 future deaths averted
Gavi’s vaccine portfolio has diversified over time
5
Uptake of
vaccines
in RI/mass
preventive
campaigns
YF
routine
Measles
2nd dose
Hib
Pentavalent
YF
campaigns
Hepatitis B
Rotavirus
PCV
YF
stockpile
Outbreak
response
Men A RI/MPC
HPV RI
Measles rubella
JE
Typhoid
Meningitis
stockpile
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016+
Learning
agenda
Cholera
Malaria
Rabies
YF
campaigns
Year of investment decision
Elimination/
eradication IPV
Measles
campaigns
JE routine
Ebola
Measles
outbreak
response
HPV
multi-age
cohort
Vaccine investments increasingly targeted at specific sets of countries
6
Targeted*
Universal*
Yellow Fever
(YF) routine
Measles
2nd dose
Hib
Pentavalent
YF
campaigns
Hepatitis B Rotavirus
PCV
YF
stockpile
Meningitis
stockpile
HPV
multi-age
cohort
Measles
rubella
JE
Typhoid
Meningitis A
RI/MPC
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016+
Other*
Cholera
Malaria
Rabies
YF
campaigns
IPV
Measles
campaigns
Ebola
Year of investment decision
Measles
outbreak
response
*Universal: all Gavi countries; Targeted: focused on sub-set of GAVI countries; Other: outbreak response, learning agenda
HPV RI
7
VIS is aligned with Gavi’s strategic cycle and financial ‘replenishment’
VIS #1 MenA,
JE, HPV
Rubella,
Typhoid
conjugate
VIS #2 YF mass campaigns,
Cholera stockpile,
Rabies/cholera studies,
Malaria – deferred
2011-2015 Strategic
period
2011 2015 2008 2012 2013 2016 2017 2018 2020
2016-2020 Strategic
period
VIS #3
2021
2021-2025
2014
RTS,S pilot
funding
decision
2022 2023 2024 2025 2019
A robust and evidence-based process will be conducted over the next 18 months
8
Km 1: What
is burden of
disease?
Km 2:
What is the
appropriate
vaccination
strategy?
Km 3:
What is the
demand in
Gavi
countries?
Km 4:
Would it be
feasible and
what would it
cost?
Km 5:
What would
be the
impact?
Km 6:
How does it
compare to other
potential
investments and
current portfolio?
EXIT
Final
Investment
Decisions
Oct 2017: decision framework(s)
May 2018: shortlist
Oct 2018: vaccine investment decisions
VIS 2013
9
WHO landscape analysis: the starting point
• Vaccines already licensed, not on GAVI list
• Vaccines that might be licensed by 2023
• Incremental changes to existing policy or vaccines
10
Preliminary list to be further reviewed:
Dengue
Hepatitis A
Hepatitis E
Influenza seasonal, maternal (pandemic?)
Malaria (refresh with no decision in 2018)
Mening CYWX
Mumps/MMR
Rabies, Rabies Ig/mAb
Typhoid
RSV (& RSV mAb?)
Group B strep
OCV
Diphtheria (booster, maternal)
Diphtheria antitoxin
11
Hep B birth dose
Pertussis (booster)
PCV catchup
IPV
Tetanus toxoid (booster, maternal)
Ebola (pre-emptive vaccination)
Zika
Norovirus
ETEC
HIV
TB 2nd generation
Chikungunya
CEPI vaccines?
VIS has traditionally prioritised health impact, but opportunity to broaden investment lens
12
Additional lenses for health impact?
Morbidity, AMR, strengthening delivery
platforms
Looking beyond direct health impact?
“Global public good” vaccines
(e.g., epidemics; eradication)
Current VIS
Overall and
U5 mortality
Procurement
cost per
deaths
averted
Previous VIS
Should Gavi consider others investments or ‘signalling’ beyond funding broad use?
• Global stockpile
• Learning agenda
• Signalling future priorities (vaccines in 5-10 year window)
13
Potentially taking a longer-term view within the VIS
14
VIS: 5 year
scope
Vaccine development: 10+ years
2019 - 2023
Long-term
guidance within
the VIS?
Questions for discussion
1. How can we align Gavi and PDVAC prioritisation of pipeline
vaccines?
2. To what extent can PDVAC help guide Gavi assessment of longer
term (‘VIS+’) vaccine priorities?
3. What (non-binding) guidance from Gavi would be helpful to focus
vaccine R&D and how does that fit in with WHO/PDVAC work on
PPCs/TPPs?
15